Inhibrx Biosciences INBX
NASDAQ INBX
$98.98 +1.05 (+1.07%)
As of: Oct 2, 2026 · 10:28 AM EDT

Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) recorded Accumulated Expenses of $15.77 million in Q2 2026, down 44.6% from $28.48 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2026) Analysis & Trends

At the end of FY2025, Inhibrx Biosciences reported Accumulated Expenses of $25.53 million, down 14.6% from FY2024.

  • Across earlier years, Accumulated Expenses came in at $29.89 million in FY2024 (-31.0%) and $43.3 million in FY2023.
  • The Q2 2026 figure is the lowest quarterly Accumulated Expenses in data going back to Q4 2023.
  • On a year-over-year basis, Accumulated Expenses rose in 1 of the last five quarters, with an average decline of 16.1%.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Inhibrx Biosciences 1.47 Bn 1.47 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.77 Mn
Dec 31, 2025 25.53 Mn
Sep 30, 2025 26.96 Mn
Jun 30, 2025 28.48 Mn
Mar 31, 2025 32.77 Mn
Dec 31, 2024 29.89 Mn
Sep 30, 2024 29.89 Mn
Jun 30, 2024 23.86 Mn
Dec 31, 2023 43.30 Mn
API Access

Inhibrx Biosciences Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=INBX&period=max&api_key=YOUR_API_KEY